← Guangdong Zhongsheng Pharmaceutical overview

Guangdong Zhongsheng Pharmaceutical vs Sichuan Kelun Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Guangdong Zhongsheng Pharmaceutical Co Ltd (002317.CS)

Q3 202620 Jul – 8 Oct 2026

▲3▼1

Zhongsheng's weight-loss drug hits Phase III goal, but profit slumps

RAY1225 weight-loss trial succeeds The company's once-every-two-weeks weight-loss injection RAY1225 met the main goal of its late-stage trial, cutting body weight by 22.24% with good safety. This is the biggest value driver: it raises the odds of a future blockbuster obesity drug, though approval is still not guaranteed.
The Phase III success is the strongest new catalyst for the stock's long-term value.
MASH drug gets fast-track review ZSP1601 tablets for fatty liver disease (MASH) were accepted into China's breakthrough therapy program after positive mid-stage data showing less liver scarring and fat. Fast-track status can speed up approval and signals the drug is promising, supporting the company's pipeline value.
A new regulatory milestone for a second innovative drug adds to the pipeline story.
Interim profit falls 40.7% First-half 2026 net profit dropped 40.70% to 111 million yuan and revenue fell 23.03% to 1 billion yuan. The existing business is shrinking, which is a real counterweight: the exciting pipeline news does not yet pay the bills, and weak earnings can cap the stock.
The profit decline is the main negative force and the honest counterweight to the pipeline optimism.
New eye-drop approval and Japan patent Zhongsheng won Chinese approval to sell its allergy eye drop Emedastine Difumarate, a small but real new revenue source. It also secured the core Japanese patent for RAY1225, strengthening long-term protection of its key obesity drug in a major market.
These are smaller but concrete new positives on top of the pipeline news.

August 202620 Jul – 8 Oct 2026

▲3▼1

Zhongsheng's weight-loss drug hits Phase III goal, but profit slumps

RAY1225 weight-loss trial succeeds The company's once-every-two-weeks weight-loss injection RAY1225 met the main goal of its late-stage trial, cutting body weight by 22.24% with good safety. This is the biggest value driver: it raises the odds of a future blockbuster obesity drug, though approval is still not guaranteed.
The Phase III success is the strongest new catalyst for the stock's long-term value.
MASH drug gets fast-track review ZSP1601 tablets for fatty liver disease (MASH) were accepted into China's breakthrough therapy program after positive mid-stage data showing less liver scarring and fat. Fast-track status can speed up approval and signals the drug is promising, supporting the company's pipeline value.
A new regulatory milestone for a second innovative drug adds to the pipeline story.
Interim profit falls 40.7% First-half 2026 net profit dropped 40.70% to 111 million yuan and revenue fell 23.03% to 1 billion yuan. The existing business is shrinking, which is a real counterweight: the exciting pipeline news does not yet pay the bills, and weak earnings can cap the stock.
The profit decline is the main negative force and the honest counterweight to the pipeline optimism.
New eye-drop approval and Japan patent Zhongsheng won Chinese approval to sell its allergy eye drop Emedastine Difumarate, a small but real new revenue source. It also secured the core Japanese patent for RAY1225, strengthening long-term protection of its key obesity drug in a major market.
These are smaller but concrete new positives on top of the pipeline news.

Latest20 Jul – 8 Oct 2026

▲3▼1

Zhongsheng's weight-loss drug hits Phase III goal, but profit slumps

RAY1225 weight-loss trial succeeds The company's once-every-two-weeks weight-loss injection RAY1225 met the main goal of its late-stage trial, cutting body weight by 22.24% with good safety. This is the biggest value driver: it raises the odds of a future blockbuster obesity drug, though approval is still not guaranteed.
The Phase III success is the strongest new catalyst for the stock's long-term value.
MASH drug gets fast-track review ZSP1601 tablets for fatty liver disease (MASH) were accepted into China's breakthrough therapy program after positive mid-stage data showing less liver scarring and fat. Fast-track status can speed up approval and signals the drug is promising, supporting the company's pipeline value.
A new regulatory milestone for a second innovative drug adds to the pipeline story.
Interim profit falls 40.7% First-half 2026 net profit dropped 40.70% to 111 million yuan and revenue fell 23.03% to 1 billion yuan. The existing business is shrinking, which is a real counterweight: the exciting pipeline news does not yet pay the bills, and weak earnings can cap the stock.
The profit decline is the main negative force and the honest counterweight to the pipeline optimism.
New eye-drop approval and Japan patent Zhongsheng won Chinese approval to sell its allergy eye drop Emedastine Difumarate, a small but real new revenue source. It also secured the core Japanese patent for RAY1225, strengthening long-term protection of its key obesity drug in a major market.
These are smaller but concrete new positives on top of the pipeline news.

Sichuan Kelun Pharmaceutical Co Ltd (002422.CS)

Q3 202627 Jul – 8 Oct 2026

▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.
Shows pipeline progress that can lift long-term growth expectations for the stock.
National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.
Directly increases expected product demand and market share, a core earnings driver.
Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.
Earnings growth and shareholder returns are the main fundamental supports for the share price.
Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.
These are the main counterweights that could hurt sentiment and valuation.

September 202627 Jul – 8 Oct 2026

▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.
Shows pipeline progress that can lift long-term growth expectations for the stock.
National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.
Directly increases expected product demand and market share, a core earnings driver.
Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.
Earnings growth and shareholder returns are the main fundamental supports for the share price.
Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.
These are the main counterweights that could hurt sentiment and valuation.

Latest27 Jul – 8 Oct 2026

▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.
Shows pipeline progress that can lift long-term growth expectations for the stock.
National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.
Directly increases expected product demand and market share, a core earnings driver.
Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.
Earnings growth and shareholder returns are the main fundamental supports for the share price.
Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.
These are the main counterweights that could hurt sentiment and valuation.